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Purpose: Recent studies have showed that epithelial-mesen-
chymal transition (EMT) is a key process of glomerular and 
tubulointerstitial pathology in many chronic kidney diseases. 
However, there are no data of EMT in humane autosomal 
dominant polycystic kidney disease (ADPKD). Patients and 
Methods:  ADPKD kidneys (N = 5) with end stage renal 
disease (ESRD) and control kidneys (N = 4) were analyzed 
immnunohistochemically. We evaluated α-SMA, E-cadherin, 
vimentin, TGF-β1 and Smad 2/3 expression in ADPKD and 
compared them with those in control kidney. These immuno-
histochemical findings were quantitatively analyzed by com-
puter-assisted image analyzer and positive tubules (%). 
Results: There were severe interstitial fibrosis and prolifera-
tion of α-SMA+ myofibroblasts in ADPKD. Cystic tubular 
epithelial cells in ADPKD lost epithelial marker (E-cadherin) 
and expressed mesenchymal markers (α-SMA, vimentin). There 
were significant increases of α-SMA (34.3 ± 11.7% vs 0.9 ± 
1.5%), vimentin (19.9 ± 3.9% vs 3.3 ± 1.4%), TGF-β1 (5.42 ± 
2.83% vs 0%) and Smad 2/3 (3.4 ± 1.7% vs 0.7 ± 0.6%) in 
ADPKD kidneys compared with control kidneys evidenced by 
computer-assisted image analyzer. When we analyze the posi-
tive tubules (%), the results were the same as computer- 
assisted image analyzer. Conclusion: Our results showed that 
the end stage of ADPKD is associated with TGF-β, Smad 2/3 
and markers of EMT. It suggests that TGF-β mediated EMT 
has a role in progression of ADPKD.
Key Words: Epithelial mesenchymal transition, antosomal 
dominant polycystic kidney disease
 
INTRODUCTION
Autosomal dominant polycystic kidney disease 
(ADPKD) is a common hereditary disease, caused 
by mutations of either PKD1 or PKD2. End stage 
renal failure (ESRD) is the most dreaded compli-
cation of ADPKD. Despite recent advances in under-
standing the molecular pathogenesis and cysto-
genesis of ADPKD, and the development of ESRD 
due to polycystic kidney has remained elusive.
1-3
The interstitial fibrosis is associated uniquely 
with renal failure in ADPKD
4 and may be the 
final common pathway, in many chronic kidney 
diseases leading to ESRD. Renal interstitial fibro-
blasts are heterogeneous population that is diffi-
cult to define in situ. Recent studies have showed 
that epithelial-mesenchymal transition (EMT) can 
occur in tubular epithelial cells, which are able to 
migrate to the interstitium and produce extracel-
luar matrix protein.
5-7 A recent study showed that 
overlap of fibroblast-specific protein 1 (FSP1)+ 
and α-smooth muscle actin (α-SMA)+ cells is associ-
ated with progressive fibrogenesis in animal PKD 
model. Some FSP1+ fibroblasts are likely derived 
from tubular epithelium undergoing EMT.
8 In 
gene profiling of ADPKD, total of 87 genes were 
specifically regulated; 26 of these 87 genes were 
typical for smooth muscle, suggesting EMT as a 
pathogenetic factor in ADPKD.
9 However, there are 
no direct data of EMT in human ADPKD. 
Transforming growth factor-β (TGF-β) is needed 
to balance interactions between cells and extra-
celluar matrix. Studies of TGF-β signaling in the 
kidney had focused on the molecular biology of 
fibrogenesis. In recent years, TGF-β  mediated 
glomerular and tubular epithelial cell apoptosis Seung Wan Chea and Kyu-Beck Lee 106
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Table 1. Immunohistochemical Results in Control and 
ADPKD by Morphometry Using a Color Image Analysis
and Tubular Count
 
Area fraction (%)
(measured area
(mm
2)/case)
Positive tubule (%) 
(positive/total 
tubule/case)
α-SMA* p = 0.001 p = 0.224
 Control 0.9 ± 1.5 
(5,401)
0
 (0/140)
 ADPKD 34.3 ± 11.7
 (20,6418)
2.1 ± 4.3 
(0.4/29.2)
E-cadherin p = 0.552 p = 0.460
 Control 5.2 ± 2.8 
(31,378)
69.5 ± 12.5 
(80.0/114.2)
 ADPKD 5.7 ± 3.2
 (34,753)
73.9 ± 11.7 
(33.2/44.6)
Vimentin* p = 0.002 p = 0.002
 Control 3.3 ± 1.4 
(19,989)
8.3 ± 4.3 
(10.2/143.0)
 ADPKD 19.9 ± 3.9 
(119,835)
49.3 ± 16.2 
(12.8/25.1)
TGF-β1* p = 0.027 p = 0.021
 Control 0 
(33)
0 
(0.0/68.0)
 ADPKD 5.4 ± 2.8 
(32,715)
49.2 ± 19.1 
(19.5/43.2)
Smad 2/3* p = 0.040 p = 0.029
 Control 0.7 ± 0.6 
(4,101)
1.6 ± 0.1 
(1.5/95.0)
 ADPKD 3.4 ± 1.7 
(20,218)
57.2 ± 20.1 
(22.7/44.4)
ADPKD, autosomal dominant polycystic kidney disease; α-SMA,
α-smooth muscle actin; TGF-β1, transforming growth factor-β1.
Area fractions (%) are evaluated by color image analysis for 
4 fields each specimen (× 200).
Positive tubules (%) are evaluated as percent of positive 
tubules/total tubules (× 200).
Data are shown as mean ± SD.
*p <0 . 0 5 .
and EMT have been proposed as putative primary 
pathomechanisms that may underlie progressive 
renal disease.
10
There are only a few data available to support 
the hypothesis that EMT has a role in human 
ADPKD. Complex mechanisms induce the EMT. 
However, it is not certain which factors are 
associated with EMT in ADPKD. To evaluate this 
hypothesis in human ADPKD, therefore, we 
immunohistochemically studied the expression of 
several makers of EMT.
PATIENTS AND METHODS
Patients
Informed consent was obtained from all patients. 
Elective transplant removal of ADPKD kidney 
was performed on renal graft recipients at the 
Samsung Medical Center. Normal renal tissue was 
obtained from tumor nephrectomies; tumor infil-
tration was excluded by histology. Tissue samples 
were fixed in 4% paraformaldehyde for immuno-
histochemistry immediately after organ removal. 
ADPKD kidneys from 5 patients (male : female = 
3 : 2, age 54 ± 7 years) who developed ESRD and 
control renal tissues from 4 patients (male : female 
= 2 : 2, age 58 ± 9 years) with renal cell carcinoma 
and normal renal function were analyzed by 
immnunohistochemistry.
 
Methods
A part of each kidney was fixed in 4% parafor-
maldehyde and was embedded in paraffin. 
Sections were cut 4 μm in thickness from paraffin 
blocks and processed for hematoxylin-eosin and 
indirect immunoperoxidase staining. After deparaf-
finization and rehydration, the sections were 
treated with proteinase K and boiled with citrate 
buffer in microwave for antigen retrieval. After 
washing, they were immersed in 3% H2O2 in 
methanol to inhibit endogenous peroxidase and 
flooded with 5% bovine albumin in PBS to inhibit 
nonspecific reactions. Anti-α-SMA (Dako, Glostrup, 
Denmark), anti-E-cadherin (Zymed Lab, San 
Fransisco, CA, USA), anti-vimentin (Dako, Glostrup, 
Denmark), anti-TGF-β1 (Santa Cruz Biotech, Santa 
Cruz, CA, USA), and anti-Smad 2/3 (Santa Cruz 
Biotech, Santa Cruz, CA, USA) were applied as 
primary antibodies. Following primary immuno-
reaction, labelling was performed using streptavi-
din-biotin immunoperoxidase method (Nichirei Epithelial-Mesenchymal Transition in ADPKD 107
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Fig. 1. Immunohistochemical staining for α-SMA. α-SMA is a mesenchymal and myofibroblast marker. In normal kidneys, 
α-SMA was negative for tubular epithelial cells; there were a few positive myofibroblasts in the interstitium (A, × 200). In 
ADPKD kidneys, the stromal cells were diffusely positive (B, × 200), and occasional epithelial cells in the dilated cysts were
positive (C and D, × 400, arrows). α-SMA, α-smooth muscle actin; ADPKD, autosomal dominant polycystic kidney disease.
Bioscience, Tokyo, Japan), and a Vectastain ABC 
kit (Vector Laboratories, Burlingame, CA, USA). 
Tissues were visualized using diaminobenzidine 
(DAB) as a chromogene (brown).
Images were captured by Baumer digital camera 
with olympus BX51 microscopy. Image analysis 
was accomplished using the public domain software 
ImageJ (available at http:/ /rsb.info.nih.gov/ij). 
Operations during analysis consisted of converting 
the images to 8-bit grey scale [256 scales of grey, 
ranging from 0 (black) to 255 (white)], plotting the 
distribution of grey values, thresholding and 
measuring total area of positive cells automatically. 
For manual counting of positive tubules, several 
randomly selected fields, totaling 0.25 mm
2 from 
the center area of the well were used. Positive 
tubules (%) were the percent of positive tubules/ 
total tubules (× 200).
All results were analyzed using SPSS 12.0 and 
expressed as mean ± standard deviation. Statistical 
significances (p < 0.05) were analyzed by using the 
Mann-Whitney test.
RESULTS
There were severe interstitial fibrosis and pro-
liferation of α-SMA+ myofibroblasts in ADPKD 
compared to control kidneys. In ADPKD, tubular 
epithelial cells of dilated cysts were occasionally 
α-SMA+ (Fig. 1). E-cadherin is an epithelial cell 
marker. There were some portions with decreased 
expression in cystic epithelial cells of large renal 
cysts in ADPKD (Fig. 2). Vimentin is a mesenchy-
mal cell marker, and it’s vimentin expression was 
increased in the stromal and cystic epithelial cells 
in ADPKD kidneys (Fig. 3). TGF-β1 and Smad 2/3 
were regulated upward in cystic epithelial cells 
(Figs. 4 and 5).
These immunohistochemical findings were 
quantitatively summarized by computer-assisted 
image analyzer and positive tubules (%) (Table 1). 
There were significant increases of α-SMA (34.3 ±
11.7 vs 0.9 ± 1.5), vimentin (19.9 ± 3.9 vs 3.3 ± 1.4), 
TGF-β1 (5.42 ± 2.83 vs 0) and Smad 2/3 (3.4 ± 1.7 
vs 0.7 ± 0.6) in ADPKD kidneys than control 
kidneys, demonstrated by computer-assisted image 
AB
CDFig. 3. Immunohistochemical staining for vimentin. Vimentin is a mesenchymal cell marker. Vimentin was positive in a 
few tubular epithelial cells of normal kidneys (A and B, × 200). In ADPKD kidneys, vimentin expression was increased
in the stromal and cystic epithelial cells (C, × 200 and D, × 400). ADPKD, autosomal dominant kidney disease.
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Fig. 2. Immunohistochemical staining for E-cadherin. E-cadherin is an epithelial cell marker. E-cadherin was widely 
expressed in distal tubular and collecting duct epithelial cells of normal kidneys (A, × 200). In ADPKD kidneys, the 
E-cadherin expression pattern was heterogeneous; there were portions in cystic epithelial cells of large renal cysts with 
decreased expression (B, × 200, C and D, × 400). ADPKD, autosomal dominant kidney disease.
AB
CD
AB
CDFig. 4. Immunohistochemical staining for TGF-β1. TGF-β1 was negative in the normal kidneys (A, × 200 and B, × 400). 
In ADPKD kidneys, TGF-β1 was upregulated in cystic epithelial cells (C and D, × 400). TGF-β1, transforming growth 
factor-β1; ADPKD, autosomal dominant kidney disease.
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Fig. 5. Immunohistochemical staining for Smad 2/3. Smad 2/3 showed sparse weakly positive cells in the normal kidneys
(A, × 200 and B, × 400). The cystic epithelial cells showed moderately positive reactions in ADPKD kidneys (C and D,
× 400). ADPKD, autosomal dominant kidney disease.
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Table 2. Location of Phenotypic Markers in ADPKD
Marker Normal TE Cystic TE Interstitial fibroblast
α-SMA - + +++
E-cadherin + - -
Vimentin ± ++ +++
TGF-β1+ + + + -
Smad 2/3 + + -
ADPKD, autosomal dominant polycystic kidney disease; TE, tubular epithelium; α-SMA, α-smooth muscle actin; TGF-β1, transforming
growth factor-β1.
analyzer. When we analyzed the positive tubules 
(%), the results were the same as computer-as-
sisted image analyzer. Large cystic tubular cells in 
ADPKD showed many α-SMA+, vimentin++ and 
E-cadherin- (Table 2). 
DISCUSSION
Human ADPKD is a heterogenic genetic disorder 
that progresses to ESRD. Progression to ESRD in 
ADPKD is associated with not only forming cysts, 
but also the accumulation of interstitial collagens, 
presumably because of proliferation of fibro-
blasts.
4,11 As cysts arise from only a small percentage 
of nephrons, other downstream mechanisms are 
important in progression to ESRD in ADPKD. In 
our study, proliferation of α-SMA+ myofibroblasts 
and interstitial fibrosis were key features of ADPKD 
with ESRD. α-SMA is normally synthesized by 
vascular smooth muscle cells and myofibroblasts 
differ from fibroblasts in granulation tissue. The 
origin of contractile myofibroblasts has not been 
easy to characterize. The conventional view is that 
these myofibroblsts are originated by differen-
tiation of resident renal fibroblast, or migration of 
pericytes, or tubular epithelia cells by EMT. 
EMT and transdifferentiation are concepts which 
originally belong to embryology and oncology. 
Cell shifting between epithelial and mesenchymal 
phenotype, by turning on and off specific genes 
during development, is a well recognized mecha-
nism that characterizes the embryonal plasticity.
12 
EMT can also play a key element in metastasis of 
tumors derived from epithelial tissues.
13 Recently 
emerging evidences suggest that EMT can be an 
important role in several glomelulonephritis,
14,15 
peritoneal fibrosis of peritoneal dialysis,
16 failing 
renal transplants
17 and diabetic nephropathy.
2 
However, there are few data of EMT available in 
human ADPKD.
In a recent study by Okada et al.,
8 many nono-
verlapping as well as fewer overlapping popula-
tions of FSP1+ and α-SMA+ cells shared in the 
collagen expression were found to be associated 
with progressive fibrogenesis in pcy mice under-
going cystogenesis. Some FSP1+ fibroblasts are 
likely derived from tubular epithelium undergoing 
EMT, whereas α-SMA +, VIM-cells probably re-
present vascular smooth muscle cells or pericytes 
surviving vessel attenuation during the chaos of 
fibrogenesis. A recent study by Schieren et al.
9 
showed that total of 87 genes in gene profiling of 
ADPKD were specifically regulated; 26 of these 87 
genes were typical for smooth muscle, suggesting 
EMT as a pathogenetic factor in ADPKD. They 
showed that smooth muscle actin and caldesmon 
were mainly expressed in the interstitium of 
ADPKD kidneys. In our study, tubular epithelial 
cells in ADPKD lost epithelial marker (E-cadherin) 
and expressed mesenchymal markers (α-SMA, 
vimentin). These finding suggest that EMT has an 
important role in progression in ADPKD.
Since the discovery of TGF-β as a key mediator 
of glomerular and tubulointerstitial fibrosis in 
many chronic kidney diseases over a decade ago, 
studies of TGF-β signaling had been focused on 
the cell proliferation and extracellular-matirx syn-
thesis.
18 In recent years, TGF-β signaling was found 
to play central role in renal fibrosis
19 by EMT.
20,21 
In the present study, we showed that TGF-β-Smad 
signaling was regulated upward in ADPKD, thus Epithelial-Mesenchymal Transition in ADPKD 111
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suggesting that TGF-β-Smad signaling is associated 
with renal EMT and renal fibrosis in ADPKD. It 
is highly likely that cyst cell proliferation and fluid 
secretion initiated the renal cysts, that enlarged 
cyst then stretched tubular cells that would secrete 
the TGF-β, and that increased TGF-β  mediated 
EMT and interstitial fibrosis. In future studies, 
therefore, we plan to suppress TGF-β and EMT to 
delay the clinical course to ESRD in ADPKD. 
In summary, α-SMA+ myofibroblasts and inter-
stitial fibrosis were key features of ADPKD with 
ESRD. Cystic tubular epithelial cells lost epithelial 
marker and expressed mesenchymal markers. 
TGF-β-Smad signaling was regulated upward in 
ADPKD, suggesting that TGF-β  mediated EMT 
has a role in progression of ADPKD.
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